continu
major
public
health
problem
new
safer
effect
therapi
need
therapeut
approv
clinic
use
vari
degre
side
effect
none
erad
protein
therapeut
typic
cell
targetspecif
rel
current
antibodi
therapeut
domin
protein
therapeut
monoclon
antibodi
mab
approv
clinic
howev
mab
approv
therapi
viral
diseas
human
mab
synagi
one
approv
fda
viral
diseas
howev
prevent
identif
novel
potent
broadli
neutral
antibodi
bnab
last
sever
year
gave
new
hope
old
idea
use
antibodi
therapeut
attempt
use
bnab
alon
combin
compon
chimer
antigen
receptor
car
bispecif
cell
engag
bite
bispecif
protein
result
promis
result
vitro
vivo
major
problem
known
bnab
none
neutral
isol
result
gener
escap
mutant
isol
includ
enter
cell
use
coreceptor
bind
primari
receptor
recent
engin
solubl
one
domain
bind
neutral
test
isol
compon
bispecif
multival
thu
hypothes
bispecif
fusion
protein
contain
fuse
antibodi
arm
bind
nk
cell
would
presum
neutral
isol
also
could
guid
activ
natur
killer
nk
cell
find
kill
infect
cell
express
envelop
glycoprotein
env
surfac
capabl
nk
cell
kill
target
cell
specif
use
bispecif
antibodi
target
cell
demonstr
year
howev
rel
recent
bispecif
molecul
call
bispecif
killer
cell
engag
bike
success
use
cancer
clinic
gener
larg
fusion
protein
kda
penetr
bloodbrain
barrier
bbb
diffus
lymphoid
tissu
mostli
replic
rel
slow
decreas
size
protein
dramat
increas
effect
diffus
coeffici
eg
decreas
size
kda
kda
increas
diffus
normal
solid
tissu
therefor
attempt
decreas
size
bike
also
use
antibodi
domain
binder
recent
identifi
hypothes
bike
gener
fuse
one
domain
flexibl
linker
antibodi
domain
binder
would
rel
small
size
could
allow
effect
penetr
tissu
guid
nk
cell
kill
infect
cell
major
compon
bike
antibodi
bind
previous
report
antibodi
anim
origin
anim
antibodi
human
eg
similar
sequenc
human
antibodi
howev
probabl
immunogen
administ
human
still
averag
higher
fulli
human
therefor
use
two
vh
antibodi
domain
ad
deriv
human
librari
display
phage
bind
high
affin
highli
specif
allotyp
show
small
bike
construct
fuse
ad
retain
high
affin
specif
bind
importantli
presenc
cell
express
env
bike
activ
specif
jurkat
cell
well
induc
degranul
nk
cell
result
kill
envexpress
cell
furthermor
bike
mediat
effect
kill
infect
cell
human
peripher
blood
mononuclear
cell
pbmc
knowledg
first
human
domainbas
bike
first
base
found
one
report
publish
extend
abstract
bike
base
llama
domain
possibl
bike
bind
isol
small
size
fulli
human
origin
combin
highaffin
specif
activ
interact
result
lysi
infect
cell
suggest
promis
candid
therapeut
worth
evalu
anim
model
potenti
human
therapi
infect
final
goal
erad
previous
identifi
antibodi
domain
ad
bind
high
affin
human
fuse
flexibl
linker
engin
one
domain
solubl
bind
high
affin
fig
bike
design
exhibit
singl
homogen
band
reduc
nonreduc
sdspage
gel
molecular
weight
mw
correspond
calcul
one
approxim
kda
fig
solubl
precipit
even
concentr
higher
mgml
ran
monom
size
exclus
chromatographi
fig
previous
show
antibodi
domain
possess
fold
higher
affin
affin
contain
also
higher
measur
biacor
fig
b
associ
rate
constant
lower
vs
respect
dissoci
rate
constant
much
lower
vs
respect
result
lower
equilibrium
dissoci
constant
k
higher
affin
compar
k
nm
vs
nm
respect
similar
high
affin
bind
also
measur
use
elisa
although
somewhat
lower
vs
nm
fig
two
bike
also
retain
high
affin
nm
bind
arm
measur
elisa
fig
expect
similar
bind
affin
taken
togeth
data
demonstr
bispecif
highaffin
bind
new
bike
next
evalu
whether
two
bike
bind
specif
express
cell
fig
bound
strongli
purifi
nk
cell
low
concentr
nm
measur
flow
cytometri
fig
expect
bound
nk
cell
effici
compar
ad
bike
bound
compar
cell
choza
cell
perman
express
fig
untransfect
cell
choza
cell
fig
e
interestingli
fluoresc
shift
bike
bind
cell
substanti
larger
bind
cell
consist
bind
two
env
binder
two
cell
line
supplement
fig
indic
choza
cell
express
higher
level
surfaceassoci
cell
transfect
result
suggest
bind
specif
cell
surfac
associ
assess
whether
bike
engag
cell
surfac
could
mediat
function
activ
express
jurkat
cell
jurkat
cell
monitor
activ
cytokin
secret
jurkat
cell
engag
initi
activ
signal
chain
ultim
lead
dephosphoryl
ntafp
nuclear
factor
activ
tcell
express
luciferas
promega
adcc
report
bioassay
thu
activ
signal
could
monitor
test
luciferas
activ
compar
adcc
capac
bike
also
measur
adcc
activ
signal
mediat
fc
fusion
protein
bival
bike
specif
activ
jurkat
cell
presenc
cell
fig
incub
bike
jurkat
cell
absenc
target
cell
presenc
cell
nonexpress
could
induc
luciferas
signal
demonstr
high
specif
bike
importantli
activ
jurkat
cell
low
concentr
rlu
nm
case
activ
higher
indic
correl
bind
affin
bike
function
activ
also
measur
cytokin
secret
jurkat
cell
bound
bike
crosslink
achiev
either
bival
mous
antiflag
antibodi
cell
coincub
jurkat
cell
bike
opson
cell
result
releas
fig
consist
result
obtain
use
posit
control
bival
contrast
bike
alon
incub
cell
alon
induc
secret
demonstr
high
specif
bike
higher
affin
induc
p
less
indic
could
correl
affinityavid
cytokin
releas
activ
howev
cell
stimul
cell
almost
effect
suggest
role
avid
effect
result
demonstr
bike
could
specif
engag
effector
cell
surfac
activ
signal
lead
cytokin
releas
next
measur
bikemedi
degranul
nk
cell
presenc
cell
nk
degranul
evalu
monitor
express
level
incub
bikeopson
target
cell
assess
specif
bike
use
three
neg
control
nk
cell
incub
bike
absenc
target
cell
presenc
env
neg
cell
nk
cell
incub
target
cell
absenc
bike
nk
cell
stimul
pmaionomycin
use
posit
control
stain
result
fig
clearli
show
induc
signific
nk
cell
degranul
compar
neg
control
fig
b
degranul
nk
cell
effect
bike
effect
correl
jurkat
cell
activ
indic
affin
import
extent
activ
effector
cell
also
note
cell
choza
cell
absenc
bike
also
could
induc
rel
weak
nk
cell
degranul
may
result
killer
immunoglobulinlik
receptor
kir
natur
cytotox
receptor
ncr
recognit
env
ligand
target
independ
mediat
nk
cell
engag
induc
express
intracellular
also
observ
although
level
high
express
supplement
fig
consist
previou
observ
comprehens
sensit
marker
nk
cell
activ
cytokin
note
level
lower
induc
base
may
result
differ
experiment
condit
differ
env
express
level
nk
cell
donor
incub
time
result
demonstr
bike
specif
engag
nk
cell
presenc
target
cell
use
three
differ
model
assess
kill
activ
new
bike
first
one
base
choza
cell
line
transfect
perman
express
case
cell
kill
measur
flow
cytometrybas
method
target
cell
discrimin
effector
cell
prelabel
fluoresc
dye
incub
bike
effector
cell
dead
target
cell
differenti
pi
stain
bike
specif
mediat
cell
kill
nk
cell
presenc
cell
fig
effect
maxim
kill
low
concentr
pm
cell
kill
efficaci
lower
lowest
affin
exhibit
lowest
cell
kill
efficaci
correl
capac
induc
nk
cell
degranul
kill
activ
significantli
reduc
presenc
nm
indic
specif
kill
target
cell
supplement
fig
evalu
bike
mediat
kill
cell
use
differ
assay
base
measur
membran
integr
cell
chronic
cell
stabli
express
structur
protein
includ
env
frequent
use
model
chronic
infect
case
effect
mediat
cell
kill
pbmc
fig
bike
effect
correl
affin
activ
assay
describ
anoth
set
experi
use
acut
infect
cell
cell
infect
target
cell
adcc
assay
perform
fourday
postinfect
infect
cem
cell
express
signific
amount
env
death
due
infect
per
se
rel
low
adcc
assay
show
low
concentr
bike
nm
bike
well
mediat
specif
kill
infect
cem
cell
pbmc
supplement
fig
bike
effect
also
use
primari
isol
infect
cell
detect
bike
mediat
kill
monitor
luciferas
activ
target
cell
observ
higher
kill
activ
data
shown
result
suggest
bike
promis
candid
evalu
anim
model
eventu
human
import
role
nk
cell
mediat
adcc
infect
well
document
past
adcc
patient
mediat
endogen
igg
exogen
therapeut
mab
fc
bind
activ
receptor
surfac
nk
demonstr
adcc
function
nk
cell
could
altern
induc
bike
consist
bind
antibodi
domain
solubl
onedomain
knowledg
among
first
report
bike
infect
although
awar
ongo
studi
studi
complet
extend
abstract
recent
use
bike
promis
new
approach
nk
cell
effector
cell
rel
refractori
infect
although
report
nk
cell
express
could
infect
cytolyt
nk
cell
rare
express
besid
infect
progress
phenotyp
nk
cell
shift
cytokin
secret
popul
phenotyp
expand
cytotox
along
diminish
indic
nk
cell
effect
effector
cell
addit
nk
mediat
cell
kill
mediat
reli
kirhlai
match
subject
inhibit
nk
cell
inhibitori
receptor
evolv
strategi
thu
recruit
nk
cell
target
could
effect
novel
strategi
infect
major
uniqu
featur
bike
bind
cell
mediat
onedomain
bind
isol
therefor
one
could
hypothes
bike
construct
could
presum
abl
kill
cell
infect
isol
escap
resist
viru
may
difficult
although
futur
experi
need
prove
statement
furthermor
one
envis
bike
could
also
act
entri
inhibitor
independ
effect
nk
cell
could
lead
synergist
effect
anoth
uniqu
featur
bike
base
fulli
human
molecul
engag
moieti
bike
base
antibodi
domain
develop
human
vh
librari
use
phage
display
antibodi
domain
high
affin
nm
specif
allotyp
independ
bind
highli
desir
properti
efficaci
vivo
thu
could
potenti
bypass
hurdl
encount
iggfc
mediat
adcc
competit
endogen
limit
due
vf
well
nonspecif
engag
antibodi
domain
also
devoid
nglycosyl
ie
contain
glycan
fc
could
complic
iggfc
mediat
adcc
differ
construct
link
two
singl
fulli
human
domain
via
three
repeat
polypeptid
gggg
unlik
typic
bike
consist
two
tandem
singl
chain
variabl
fragment
scfv
usual
encount
undesir
express
fold
bike
contain
two
immunoglobulin
domain
total
molecular
weight
kd
fig
simpl
format
render
bike
high
express
e
coli
mgl
homogen
fold
solut
fig
knowledg
first
bike
report
entir
base
domain
therefor
rel
small
size
small
size
import
penetr
normal
tissu
includ
lymphoid
tissu
mostli
replic
could
significantli
higher
antibodi
fragment
antibodi
fusion
protein
exampl
previou
studi
shown
full
size
antibodi
mw
kda
effect
diffus
coeffici
lower
solid
tissu
molecul
therefor
effect
size
could
signific
bike
also
fulli
human
may
exhibit
immunogen
administ
human
howev
experi
anim
model
infect
ultim
human
clinic
trial
show
whether
immunogen
immunogen
immunogen
previous
llama
antibodi
domain
bind
high
affin
use
gener
two
bike
target
carcinoembryon
antigen
cea
bike
success
mediat
lysi
target
cell
thu
demonstr
first
time
antibodi
domain
function
compon
bike
present
evid
confirm
statement
expand
use
fulli
human
domain
fuse
anoth
human
protein
domain
bike
describ
bound
specif
high
affin
recombin
protein
cell
surfac
associ
protein
fig
bind
function
demonstr
multipl
experiment
evid
studi
activ
jurkat
cell
dephosphoryl
nfatp
follow
luciferas
express
cytokin
secret
bike
could
also
induc
nk
cell
degranul
encount
target
cell
activ
nk
cell
could
kill
target
cell
express
env
importantli
small
bike
could
effect
engag
pbmc
kill
chronic
infect
cell
cell
constitut
express
env
well
acut
infect
cem
cell
subtyp
b
strain
recent
primari
isol
result
promis
although
experi
anim
model
infect
ultim
human
clinic
trial
show
whether
highli
effect
vivo
note
efficaci
bike
engag
effector
cell
except
high
bike
stimul
jurkat
cell
induc
kill
cell
low
pm
fig
interestingli
assay
could
engag
effector
cell
effici
effect
correl
bind
affin
nm
nm
fc
result
indic
bind
affin
correl
function
efficaci
given
ident
epitop
bind
site
similar
epitop
therefor
one
could
specul
high
affin
bike
could
function
effect
bnab
bind
site
epitop
although
compar
side
side
adcc
efficaci
bike
bnab
studi
high
affin
bike
could
also
import
chronic
infect
patient
constant
activ
may
exhaust
nk
lead
decreas
express
due
cleavag
matrixmetalloproteas
anoth
exampl
numer
way
use
escap
immun
surveil
high
affin
bike
could
result
bind
nk
cell
even
express
level
low
anoth
consider
nk
cell
solid
lymphoid
organ
mucosa
mostli
replic
mainli
phenotyp
rather
cytotox
due
decreas
express
tissuehom
receptor
nk
cell
high
affin
could
maxim
engag
low
cell
number
solid
lymphoid
tissu
kill
cell
also
import
case
env
express
low
surfac
concentr
especi
chronic
latent
infect
therefor
high
bind
affin
bike
could
import
vivo
efficaci
high
affin
howev
could
lead
specif
issu
thu
cell
kill
assay
incorpor
variou
control
determin
possibl
nonspecif
bike
result
includ
activ
cytokin
secret
jurkat
cell
nk
cell
degranul
kill
envexpress
cell
infect
cell
consist
highli
depend
presenc
bike
target
cell
bike
alon
could
neither
activ
jurkat
induc
degranul
nk
cell
coincub
target
cell
effector
cell
absenc
bike
coincub
envneg
control
cell
effector
cell
presenc
bike
could
lead
target
cell
kill
although
nk
cell
degranul
assay
coincub
nk
cell
cell
absenc
bike
induc
low
express
may
result
direct
engag
receptor
nk
cell
surfac
kir
independ
bike
note
previous
shown
onedomain
bind
mhc
class
ii
thu
data
suggest
activ
bike
highli
specif
new
bike
highli
function
kill
infect
cell
report
fulli
human
bike
base
protein
domain
exhibit
highli
specif
highaffin
bind
also
possess
good
drugabl
properti
includ
rel
high
level
express
therefor
alon
combin
inhibitor
could
use
develop
novel
safe
therapeut
potenti
tool
erad
recombin
lsevhlsf
produc
group
previous
bind
antibodi
domain
express
bacteria
purifi
ninta
resin
qiagen
valencia
ca
subclon
psectag
b
vector
express
freestyletm
cell
purifi
use
protein
sepharos
resin
invitrogen
codon
optim
env
sequenc
cladeb
isol
synthes
subclon
psectag
b
express
choza
cell
purifi
ninta
fc
fusion
protein
express
freestyletm
cell
purifi
protein
use
neg
control
infect
cell
kill
experi
human
monoclon
antibodi
target
clone
vector
express
choza
cell
purifi
protein
resin
vector
kindli
provid
denni
burton
scripp
research
institut
la
jolla
ca
usa
psectag
b
vector
purchas
invitrogen
follow
antibodi
purchas
mous
abcam
cambridg
usa
phycoerythrin
pe
conjug
mous
antiflag
phycoerythrin
pe
conjug
mous
mous
clone
miltenyi
bergisch
gladbach
germani
hrpconjug
mous
antiflag
tag
sigmaaldrich
choza
cell
suspens
deriv
cell
adapt
nonserum
medium
choza
cell
stabl
cell
line
develop
laboratori
dsd
express
cultur
opticho
medium
invitrogen
contain
zeocin
mm
glutamin
similarli
cell
express
maintain
dmem
complet
medium
invitrogen
contain
fb
invitrogen
zeocin
follow
cell
line
purchas
cell
constitut
express
env
atcc
freestyletm
invitrogen
express
jurkat
cell
promega
cell
provid
dr
alexandra
trkola
aid
research
refer
reagent
program
nation
institut
allergi
infecti
diseas
bethesda
md
primari
isol
isol
chines
posit
subject
human
blood
obtain
healthi
donor
approv
human
subject
agreement
collect
blood
donor
approv
nation
cancer
institutefrederick
research
donor
program
gene
obtain
fuse
dna
dna
overlap
extens
pcr
use
follow
primer
sens
antisens
sens
antisens
sfi
digest
bike
gene
subclon
sfi
linear
vector
contain
infram
c
termin
tag
follow
flag
tag
dykddddk
recombin
bike
plasmid
express
cell
purifi
onestep
ninta
chromatographi
puriti
check
sdspage
reduc
nonreduc
condit
fig
homogen
confirm
superdex
gl
chromatographi
ge
healthcar
cat
fig
column
calibr
protein
molecular
mass
standard
kda
kda
aprotinin
kda
ribonucleas
kda
ovalbumin
kda
bsa
purifi
bike
pb
load
preequilibr
column
elut
pb
mlmin
protein
concentr
measur
spectrophotometr
nanovu
ge
healthcar
protein
store
use
notic
storag
could
chang
properti
signific
degre
affect
conclus
plate
costar
coat
ngwell
phosphatebuff
salin
pb
overnight
follow
block
pb
contain
nonfat
milk
mpb
h
room
temperatur
plate
incub
serial
dilut
bike
fold
begin
concentr
h
room
temperatur
extens
wash
pb
contain
bound
bike
detect
hrpconjug
mous
antiflag
tag
signal
record
monitor
optic
absorb
nm
ad
substrat
tmb
sigmaaldrich
halfmaxim
bind
effect
elisa
concentr
design
concentr
optic
densiti
od
maxim
valu
kinet
bind
bike
test
spr
analysi
biacor
ge
healthcar
use
singlecycl
approach
accord
manufactur
instruct
briefli
pure
buffer
sodium
acet
ph
directli
immobil
onto
sensor
chip
standard
aminecoupl
method
refer
cell
inject
dimethyaminopropi
carbodiimid
ethanolamin
without
inject
bike
dilut
run
buffer
hbsep
mm
hepe
ph
nacl
mm
edta
surfact
assay
concentr
nm
chip
regener
mm
glycin
ph
nacl
sensorgram
analyz
biaevalu
softwar
kinet
constant
obtain
fit
sensorgram
pbmc
isol
peripher
blood
healthi
donor
centrifug
ficollhypaqu
gradient
ge
health
nk
cell
enrich
human
pbmc
use
nk
cell
isol
kit
ii
neg
select
mode
miltenyi
biotec
purifi
nk
cell
detect
incub
biotinyl
antibodi
develop
follow
streptavidinfitc
pe
conjug
mous
antihuman
antibodi
bind
nk
cell
measur
incub
nk
cell
pb
contain
bovin
serum
albumin
bsa
pbsa
nm
bike
min
room
temperatur
cell
wash
twice
pbsa
follow
incub
peconjugatedmous
antiflag
antibodi
miltenyi
biotec
min
ice
wash
cell
use
fluorescenceactiv
cell
sorter
fac
analysi
second
antibodi
alon
use
neg
control
bind
cell
choza
cell
without
overexpress
bike
perform
similar
procedur
experi
repeat
three
time
commerci
avail
adcc
report
bioassay
promega
use
evalu
activ
jurkat
cell
jurkat
cell
encod
luciferas
report
gene
driven
nuclear
factor
activ
cell
respons
element
nfatr
use
effector
cell
use
cell
line
stabli
express
cladeb
env
cell
target
cell
target
cell
plate
plate
densiti
cell
complet
medium
per
well
bike
serial
dilut
initi
concentr
nm
ad
well
effector
cell
ad
densiti
cell
ul
complet
medium
per
well
target
effector
cell
ratio
assay
develop
overnight
incub
use
promega
bioglo
luciferas
assay
system
cat
accord
manufactur
instruct
bike
incub
jurkat
cell
absenc
target
cell
presenc
cell
use
determin
nonspecif
activ
bike
serv
also
neg
control
experi
jurkat
cell
use
evalu
engag
effector
cell
surfac
bike
monitor
secret
jurkat
cell
cultur
medium
invitrogen
contain
fb
mm
pyruv
mm
mem
nonessenti
amino
acid
hygromycin
invitrogen
incub
bike
jurkat
cell
activ
overnight
pma
ngml
sigma
jurkat
cell
incub
bike
nm
alon
bikesmous
antiflag
mab
dilut
mixtur
bike
opson
target
cell
cell
mous
use
posit
control
incub
cell
centrifug
min
g
quantiti
human
supernat
measur
sandwich
elisa
duoset
human
kit
duoset
human
r
system
accord
manufactur
instruct
nk
cell
degranul
monitor
express
stimul
cell
surfac
express
measur
fac
base
method
describ
briefli
target
cell
cell
neg
control
cell
choza
plate
plate
densiti
cell
complet
medium
per
well
bike
ad
well
nm
final
concentr
mixtur
incub
min
allow
opson
prior
addit
effector
cell
nk
cell
ad
densiti
cell
ul
complet
medium
per
well
make
target
effector
cell
ratio
pma
ionomycin
sigma
use
posit
control
thereaft
mous
antihuman
biolegend
ad
surfac
stain
h
incub
golgistop
monensin
biolegend
ad
everi
well
continu
incub
h
cell
collect
wash
fac
buffer
pb
bsa
subject
fac
analysi
bd
flow
cytomet
cellquest
pro
softwar
use
data
acquisit
analysi
nk
cell
gate
forwardsid
scatter
fluoresc
cutoff
set
frequenc
express
nk
cell
nk
cell
group
without
ad
bike
cell
around
cutoff
correspond
boundari
three
standard
deviat
sd
dot
plot
obey
gaussian
distribut
kill
envtransfect
cell
measur
facsbas
method
describ
briefli
cell
label
sigmaaldrich
accord
manufactur
instruct
seed
plate
densiti
cell
complet
medium
per
well
bike
serial
dilut
nm
ad
well
mixtur
target
cell
bike
incub
min
allow
opson
prior
addit
effector
cell
nk
cell
cultur
complet
medium
contain
uml
human
recombin
ngml
r
system
ad
densiti
cell
ul
complet
medium
per
well
make
target
effector
cell
ratio
plate
incub
hour
propidium
iodid
pi
sigma
ad
well
incub
room
temperatur
min
sampl
dilut
fac
buffer
analyz
bd
flow
cytometri
cytotox
assay
well
triplic
cell
kill
percentag
calcul
subtract
neg
control
nk
cell
incub
absenc
bike
kill
chronic
infect
cell
pbmc
mediat
bike
evalu
use
differ
assay
base
measur
membran
integr
cell
atcc
plate
roundbottom
plate
densiti
cell
complet
medium
contain
iuml
per
well
bike
serial
dilut
nm
ad
well
mixtur
target
cell
bike
incub
min
allow
opson
prior
addit
effector
cell
pbmc
ad
densiti
cell
ul
complet
medium
per
well
make
target
effector
cell
ratio
assay
develop
overnight
incub
use
promega
homogen
membran
integr
assay
cat
accord
manufactur
instruct
merscovspecif
mab
use
neg
control
experi
perform
duplic
well
maximum
signal
max
achiev
treatment
target
cell
triton
target
cell
alon
tc
effector
cell
alon
target
cell
effector
cell
absenc
bike
bike
use
neg
control
fluresc
measur
nm
cell
kill
percentag
calcul
bike
bike
maxtc
